

## Special Issue

# Radiopharmaceuticals and Nanotechnology: From Diagnostics to Theranostic Applications

### Message from the Guest Editor

In the field of nuclear medicine and radiopharmaceuticals in the 2000s, developing and radiolabeling a nanomaterial was highly innovative in itself, even if its in vivo biodistribution was disseminated to... all the main organs of the body! However, the numerous proofs of concept and developments published in the past 10 years have raised a couple of questions that now need to be answered: how many nanoradiopharmaceuticals have been developed and published, with encouraging preclinical results but absolutely no clinical output? We hear that nanoradiopharmaceuticals are the future of nuclear medicine, but why does it take so long for a nanoradiopharmaceutical to find its place in clinical trials? Is toxicity an insurmountable hindrance? We hope this Special Issue will inspire transdisciplinary teams to join their best forces, i.e., specialized engineers, (radio)pharmacists, (radio)chemists, (radio)physicists, pharmacokinetics specialists and nuclear MDs, because that is precisely what this topic needs. Let us zoom in together to the nanoscale and take a picture of what tomorrow's radiopharmaceuticals might look like.

### Guest Editor

Dr. Philippe Garrigue

Radiopharmacy, University Hospitals of Marseille (AP-HM), Center for CardioVascular and Nutrition Research (C2VN, UMR AMU INSERM 1263 - INRAE 1260), European Center for Medical Imaging Research (CERIMED, UMS AMU CNRS 2012), Aix-Marseille University, 27 Boulevard Jean Moulin, 13005 Marseille, France

### Deadline for manuscript submissions

closed (28 February 2022)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/78419](https://mdpi.com/si/78419)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).